BusinessEyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone PaymentBy Nasdaq OMXDec 18, 2017, 1:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual MeetingBy Nasdaq OMXDec 12, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 11:30 AM UTC
BusinessProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessGalectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017By Nasdaq OMXDec 4, 2017, 9:00 PM UTC
BusinessZynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)By Nasdaq OMXDec 3, 2017, 5:01 PM UTC
BusinessInternational Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's DiseaseBy Nasdaq OMXNov 29, 2017, 1:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology PlatformBy Nasdaq OMXNov 29, 2017, 12:32 PM UTC
